was successfully added to your cart.

Your SEO optimized title page contents

Kentucky Approves Advancement in Cannabinoid Therapy

By March 4, 2014Cannabinoid

Advancement in Cannabinoid Therapy

Advancement in Cannabinoid Therapy

Kentucky took two big steps forward this last week in its efforts to legalize medical marijuana.

On Feb. 25, Senate Bill 124 (SB124) passed in the Senate, making it the first medical marijuana bill to advance in the Kentucky legislature. SB124 would authorize the University of Kentucky and University of Louisville’s medical hospitals to administer Cannabidiol (CBD) oil to patients enrolled in a U.S. Food and Drug Administration clinical trial, including children.

Kentucky would be the second state to implement a CBD oil policy that includes children; currently, only Colorado offers the program. As a result, Kentucky is suffering from a migration of families fleeing for the only medicine available to their children that is proven to work safely and effectively.

However, Quantum 9’s quality assurance experts believe that while this is a step forward, SB124 is far too specific and leaves thousands untreated. Rather, Quantum 9’s QA team is hoping to see continued support for House Bill 350 (HB350), sponsored by Representative Mary Lou Marzian.

Members of the House Health and Welfare Committee when they voted 9-5 on Feb. 27 to approve HB350, a full medical marijuana bill that would protect qualifying patients from arrest, will allow patients to cultivate limited amounts of marijuana plants, and provide safe, legal access to medical marijuana through state-regulated dispensaries.

Approved conditions to be treated with medical marijuana under HB 350 include terminal illness, peripheral neuropathy, anorexia, cancer, glaucoma, HIV positive status, AIDS, hepatitis C, amyotrophic lateral sclerosis, Crohn’s disease, agitation of Alzheimer’s disease, PTSD, diabetes, fibromyalgia, autism, ulcerative colitis, injuries that significantly interfere with daily activities, treatment of specific symptoms of a chronic or debilitating disease or medical condition or other medical conditions added by the state.

HB350 will be introduced on the Senate floor this week. A similar bill, SB43, introduced by Senator Perry Clark, was introduced on Jan 7, 2014. The head of Quantum 9’s quality assurance team is a scientific advisor to Sen. Clark, and Quantum 9 helped write a significant portion of SB43 legislation. Hopefully, SB43 will gain traction in the near future.

Quantum 9’s QA team says that while public opinion has always been high in regard to legalizing medical marijuana, it is now between 70 and 80 percent.

About Michael Mayes

As Chief Executive Officer for Quantum 9, Inc., Michael has assisted in funding some of the largest commercial cannabis projects in the world. Michael has been a cannabis investor since 2009 in Colorado’s first legal for-profit cannabis market. As the co-founder and CEO of Quantum 9, Inc., Michael has spent years designing technology and collaborating with countless consultants on the forefront of the cannabis industry. Collaborating with the brightest minds and contributing to world-class organizations has been an incredibly enlightening and rewarding experience for him. Also, he has amassed a comprehensive and award-winning team engaged globally for public policy best practices through the prioritization of environmental sustainability and patient care. Michael is a member of the International Cannabinoid Research Society (ICRS), contributor to Marijuana Business Daily, quoted in the Chicago Tribune, Tampa Tribune, Yahoo Finance, Tampa Tribune, Sativa Magazine, CBC and the Daily Herald. His media appearances include several CBS and WGN appearances and international presence on BNN Commodities in Canada. On the public policy front, Michael and his team were instrumental in their work of drafting the Kentucky Medical Marijuana Bill for Senator Perry Clark. Most recently, Michael taught a class for the International Pharmaceutical Academy in Toronto, Canada. He spoke on Cannabis Pharmacology, and the effects cannabis has on the endocannabinoid system.

One Comment

Leave a Reply